Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide
oleh: Ruben A. Ferrer, Manja Wobus, Catrin List, Rebekka Wehner, Claudia Schönefeldt, Barbara Brocard, Brigitte Mohr, Martina Rauner, Marc Schmitz, Maik Stiehler, Gerhard Ehninger, Lorenz C. Hofbauer, Martin Bornhäuser, Uwe Platzbecker
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2013-11-01 |
Deskripsi
The contribution of the bone marrow microenvironment in myelodysplastic syndrome is controversial. We therefore analyzed the functional properties of primary mesenchymal stromal cells from patients with myelodysplastic syndrome in the presence or absence of lenalidomide. Compared to healthy controls, clonality and growth were reduced across all disease stages. Furthermore, differentiation defects and particular expression of adhesion and cell surface molecules (e.g. CD166, CD29, CD146) were detected. Interestingly, the levels of stromal derived factor 1-alpha in patients’ cells culture supernatants were almost 2-fold lower (P